Overview

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
0
Participant gender:
All
Summary
A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Temple University
Collaborators:
Medical University of South Carolina
Research Foundation for Mental Hygiene, Inc.
University of Pennsylvania Perelman School of Medicine
Treatments:
Clavulanic Acid
Clavulanic Acids
Criteria
Inclusion Criteria:

- Be able to verbalize understanding of consent form, able to provide written informed
consent, and verbalize willingness to complete study procedures

- Be male or female adult volunteers ages 18-70 inclusive.

- Have a DSM-V diagnosis of cocaine use disorder, moderate to severe in early remission
with a duration of regular (weekly or more) cocaine (either snorted, smoked or
injected) for at least one year.

- Have a history and brief physical examination that demonstrate no clinically
significant contraindication for participating in the study, and/ or significant or
unstable medical or psychiatric illness.

Exclusion Criteria:

- Meets DSM-V criteria for dependence on any substance other than cocaine and mild to
moderate alcohol or marijuana (except nicotine or caffeine), determined by the
structured clinical interview for DSM-V.

- Allergy to clavulanic acid, penicillin, or any beta-lactam drug.

- Meets current or lifetime DSM-V criteria for schizophrenia or any psychotic disorder
or organic mental disorder. Subject meets current DSM-V diagnosis of any other
clinically significant psychiatric disorder that will interfere with study
participation.

- Severe physical or medical illnesses such as AIDS or active hepatitis.

- If female, tests positive on a pregnancy test, is contemplating pregnancy in the next
6 months, is nursing, or is not using an effective contraceptive method (if relevant)